Syros Pharmaceuticals Inc (NASDAQ:SYRS) traded up 10% during trading on Tuesday . The company traded as high as $10.34 and last traded at $9.89. 934,300 shares changed hands during mid-day trading, an increase of 580% from the average session volume of 137,377 shares. The stock had previously closed at $8.99.

A number of equities research analysts recently commented on the company. Oppenheimer set a $28.00 target price on Syros Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, December 13th. Cowen restated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Monday, December 11th. Piper Jaffray Companies restated an “overweight” rating and issued a $30.00 price objective on shares of Syros Pharmaceuticals in a research report on Tuesday, October 31st. Roth Capital assumed coverage on Syros Pharmaceuticals in a research report on Monday, October 23rd. They issued a “neutral” rating and a $15.00 price objective on the stock. Finally, Zacks Investment Research upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. Syros Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $26.14.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.53) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.53). analysts predict that Syros Pharmaceuticals Inc will post -2.12 earnings per share for the current fiscal year.

In other Syros Pharmaceuticals news, Director Srinivas Akkaraju bought 109,774 shares of the firm’s stock in a transaction dated Thursday, December 14th. The shares were purchased at an average price of $9.03 per share, for a total transaction of $991,259.22. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Jeremy P. Springhorn bought 15,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were acquired at an average price of $9.08 per share, for a total transaction of $136,200.00. The disclosure for this purchase can be found here. Corporate insiders own 33.60% of the company’s stock.

Several large investors have recently made changes to their positions in the company. GSA Capital Partners LLP purchased a new position in shares of Syros Pharmaceuticals during the 3rd quarter valued at approximately $240,000. Cubist Systematic Strategies LLC purchased a new position in shares of Syros Pharmaceuticals during the 3rd quarter valued at approximately $149,000. Schwab Charles Investment Management Inc. lifted its position in shares of Syros Pharmaceuticals by 95.8% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 41,709 shares of the company’s stock valued at $614,000 after buying an additional 20,409 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of Syros Pharmaceuticals during the 3rd quarter valued at approximately $975,000. Finally, Trexquant Investment LP purchased a new position in shares of Syros Pharmaceuticals during the 3rd quarter valued at approximately $282,000. Hedge funds and other institutional investors own 57.96% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/21/syros-pharmaceuticals-syrs-trading-10-higher.html.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Receive News & Stock Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related stocks with our FREE daily email newsletter.